Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Multicenter, Open-label Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

NCT06377930 is registered in ClinicalTrials.gov with Rapport Therapeutics Inc. as lead sponsor.

NCT NCT06377930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06377930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Multicenter, Open-label Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
Lead sponsor
Rapport Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 10, 2024
Completion date
September 26, 2025
Enrollment
30 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

focal onset seizures